Literature DB >> 20086140

In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.

Mohammad J Najafzadeh1, Hamid Badali, Maria Teresa Illnait-Zaragozi, G Sybren De Hoog, Jacques F Meis.   

Abstract

The in vitro activities of eight antifungal drugs against clinical isolates of Fonsecaea pedrosoi (n = 21), Fonsecaea monophora (n = 25), and Fonsecaea nubica (n = 9) were tested. The resulting MIC(90)s for all strains (n = 55) were as follows, in increasing order: posaconazole, 0.063 microg/ml; itraconazole, 0.125 microg/ml; isavuconazole, 0.25 microg/ml; voriconazole, 0.5 microg/ml; amphotericin B, 2 microg/ml; caspofungin, 2 microg/ml; anidulafungin, 2 microg/ml; and fluconazole, 32 microg/ml.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086140      PMCID: PMC2849378          DOI: 10.1128/AAC.01655-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Management of chromoblastomycosis: novel perspectives.

Authors:  Philippe Esterre; Flavio Queiroz-Telles
Journal:  Curr Opin Infect Dis       Date:  2006-04       Impact factor: 4.915

2.  Successful treatment of chromoblastomycosis of 36 years duration caused by Fonsecaea monophora.

Authors:  M J Najafzadeh; A Rezusta; M I Cameo; M L Zubiri; M C Yus; H Badali; M J Revillo; G S De Hoog
Journal:  Med Mycol       Date:  2010-03       Impact factor: 4.076

3.  Chromoblastomycosis: clinical and mycologic experience of 51 cases.

Authors:  A Bonifaz; E Carrasco-Gerard; A Saúl
Journal:  Mycoses       Date:  2001       Impact factor: 4.377

Review 4.  Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.

Authors:  Jesús Guinea; Emilio Bouza
Journal:  Future Microbiol       Date:  2008-12       Impact factor: 3.165

Review 5.  Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis.

Authors:  Marcia Garnica; Marcio Nucci; Flavio Queiroz-Telles
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

Review 6.  Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment.

Authors:  Flavio Queiroz-Telles; Phillippe Esterre; Maigualida Perez-Blanco; Roxana G Vitale; Claudio Guedes Salgado; Alexandro Bonifaz
Journal:  Med Mycol       Date:  2008-12-09       Impact factor: 4.076

7.  Genetic diversity and species delimitation in the opportunistic genus Fonsecaea.

Authors:  M J Najafzadeh; C Gueidan; H Badali; A H G Gerrits Van Den Ende; Lian Xi; G S De Hoog
Journal:  Med Mycol       Date:  2008-12-19       Impact factor: 4.076

Review 8.  Treating chromoblastomycosis with systemic antifungals.

Authors:  Alexandro Bonifaz; Vanessa Paredes-Solís; Amado Saúl
Journal:  Expert Opin Pharmacother       Date:  2004-02       Impact factor: 3.889

9.  Posaconazole treatment of refractory eumycetoma and chromoblastomycosis.

Authors:  Ricardo Negroni; Angela Tobón; Beatriz Bustamante; Maria Aparecida Shikanai-Yasuda; Hernando Patino; Angela Restrepo
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2005 Nov-Dec       Impact factor: 1.846

10.  In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis.

Authors:  R G Vitale; M Perez-Blanco; G S De Hoog
Journal:  Med Mycol       Date:  2009-02       Impact factor: 4.076

View more
  25 in total

1.  In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous exophiala species.

Authors:  M J Najafzadeh; M Saradeghi Keisari; V A Vicente; P Feng; S A A Shamsian; A Rezaei-Matehkolaei; G S de Hoog; I Curfs-Breuker; J F Meis
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

2.  In vitro antifungal susceptibility of Cladophialophora carrionii, an agent of human chromoblastomycosis.

Authors:  S Deng; G S de Hoog; H Badali; L Yang; M J Najafzadeh; B Pan; I Curfs-Breuker; J F Meis; W Liao
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

3.  Respiratory Tract Infection Caused by Fonsecaea monophora After Kidney Transplantation.

Authors:  Isabella Barbosa Cleinman; Sarah Santos Gonçalves; Marcio Nucci; Danielle Carvalho Quintella; Márcia Halpern; Tiyomi Akiti; Glória Barreiros; Arnaldo Lopes Colombo; Guilherme Santoro-Lopes
Journal:  Mycopathologia       Date:  2017-06-28       Impact factor: 2.574

4.  In vitro activities of nine antifungal drugs and their combinations against Phialophora verrucosa.

Authors:  Yali Li; Zhe Wan; Ruoyu Li
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

5.  Answer to May 2016 Photo Quiz.

Authors:  Florent Morio; Sébastien Barbarot; Samuel Pineau; Hélène Aubert; Dea Garcia-Hermoso; Sybren de Hoog; Rose-Anne Lavergne; Patrice Le Pape
Journal:  J Clin Microbiol       Date:  2016-05       Impact factor: 5.948

Review 6.  Chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Sybren de Hoog; Daniel Wagner C L Santos; Claudio Guedes Salgado; Vania Aparecida Vicente; Alexandro Bonifaz; Emmanuel Roilides; Liyan Xi; Conceição de Maria Pedrozo E Silva Azevedo; Moises Batista da Silva; Zoe Dorothea Pana; Arnaldo Lopes Colombo; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 7.  Phaeohyphomycoses, emerging opportunistic diseases in animals.

Authors:  S Seyedmousavi; J Guillot; G S de Hoog
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

8.  Chromoblastomycosis due to Fonsecaea pedrosoi and F. monophora in Cuba.

Authors:  Hamid Badali; Maydelin Fernández-González; Bita Mousavi; Maria Teresa Illnait-Zaragozi; Juan Carlos González-Rodríguez; G Sybren de Hoog; Jacques F Meis
Journal:  Mycopathologia       Date:  2013-03-08       Impact factor: 2.574

9.  In vitro antifungal activity of isavuconazole against Madurella mycetomatis.

Authors:  Wendy Kloezen; Jacques F Meis; Ilse Curfs-Breuker; Ahmed H Fahal; Wendy W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

10.  First case of Tritirachium oryzae as agent of onychomycosis and its susceptibility to antifungal drugs.

Authors:  Ali Naseri; Abdolmajid Fata; Mohammad Javad Najafzadeh
Journal:  Mycopathologia       Date:  2013-04-17       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.